• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Influenza vaccination and 1-year risk of myocardial infarction, stroke, heart failure, pneumonia, and mortality among intensive care unit survivors aged 65  years or older: a nationwide population-based cohort study
ConclusionsCompared with the unvaccinated ICU survivors, the influenza vaccinated ICU survivors had a lower 1-year risk of stroke and a lower 1-year risk of death, whereas no substantial association was observed for the risk of hospitalization for myocardial infarction, heart failure, or pneumonia. Our findings support influenza vaccination of individuals aged  ≥ 65 years.
Source: Intensive Care Medicine - June 10, 2019 Category: Intensive Care Source Type: research

Beneficial Effects of Vaccination on Cardiovascular Events: Myocardial Infarction, Stroke, Heart Failure
Influenza and pneumococcal infections have been suggested to be potential risk factors for causing adverse cardiovascular events, especially in high-risk patients. Vaccination against respiratory infections in patients with established cardiovascular disease (CVD) could serve as a potential cost-effective intervention to improve their clinical outcomes and cardiac societies have encouraged it. Previous studies have shown that influenza vaccination reduce mortality, acute coronary syndromes and hospitalization in patients with coronary heart disease (CHD) and/or heart failure (HF). However, there is a paucity of randomized ...
Source: Cardiology - November 15, 2018 Category: Cardiology Source Type: research

Impact of influenza, herpes zoster, and pneumococcal vaccinations on the incidence of cardiovascular events in subjects aged over 65  years: a systematic review
Geroscience. 2023 Jun 3. doi: 10.1007/s11357-023-00807-4. Online ahead of print.ABSTRACTThis systematic review aims to summarize the impact of vaccination against influenza, shingles, and pneumococcus on the incidence on the risk of cardiovascular events in the elderly. This protocol was developed in accordance with PRISMA guidelines. We conducted a literature search and identified all relevant articles published regarding the matter up to September 2022. We retrieved 38 studies (influenza vaccine = 33, pneumococcal vaccine = 5, and zoster vaccine = 2). A total of 28 and 2 studies have shown that influenza and pneumococcal...
Source: Herpes - June 3, 2023 Category: Infectious Diseases Authors: Alexandra Addario Thomas C élarier Bienvenu Bongue Nathalie Barth Ga ëtan Gavazzi Elisabeth Botelho-Nevers Source Type: research

Effectiveness of the influenza vaccine in preventing admission to hospital and death in people with type 2 diabetes.
Authors: Vamos EP, Pape UJ, Curcin V, Harris MJ, Valabhji J, Majeed A, Millett C Abstract BACKGROUND: The health burden caused by seasonal influenza is substantial. We sought to examine the effectiveness of influenza vaccination against admission to hospital for acute cardiovascular and respiratory conditions and all-cause death in people with type 2 diabetes. METHODS: We conducted a retrospective cohort study using primary and secondary care data from the Clinical Practice Research Datalink in England, over a 7-year period between 2003/04 and 2009/10. We enrolled 124 503 adults with type 2 diabetes. Outcome me...
Source: Canadian Medical Association Journal - July 28, 2016 Category: Journals (General) Tags: CMAJ Source Type: research

Pneumonia in the Noninstitutionalized Older Population.
CONCLUSION: Pneumonia plays an important role in the medical care of non-institutionalized older people. With the aid of the predictors identified in this study, primary care physicians can identify patients at risk, smokers can gain additional motivation to quit, treatment compliance can be increased, and patients may become more willing to be vaccinated as recommended in the current guidelines. PMID: 27697144 [PubMed - in process]
Source: Deutsches Arzteblatt International - October 5, 2016 Category: Journals (General) Tags: Dtsch Arztebl Int Source Type: research

Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate cancer, Janssen...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

POSA199 Risk of Cardiovascular Events after Streptococcus Pneumoniae Infections: Life Study
Streptococcus pneumoniae is a common cause of diseases such as community-acquired pneumonia, meningitis, and sepsis across all age groups. In Japan, routine pneumococcal vaccinations are carried out for children aged ≤5 years and older persons aged ≥65 years due to their higher risk of infection. Acute S. pneumoniae infections are reported to elevate the risk of subsequent cardiovascular events such as coronary heart disease, heart failure, arrhythmia, and stroke. In order to generate evidence for the develo pment of optimal vaccination strategies, this study analyzed the effects of S.
Source: Value in Health - January 1, 2022 Category: International Medicine & Public Health Authors: N Nishimura, H Fukuda Source Type: research

Influenza vaccination in patients with heart failure: A protocol for meta-analysis of randomized controlled trials
Discussion: This meta-analysis will evaluate the efficacy and safety of influenza vaccination in heart failure patients, providing evidence to the use of influenza vaccine in these patients. Systematic review registration: INPLASY202210115.
Source: Medicine - February 11, 2022 Category: Internal Medicine Tags: Research Article: Study Protocol Systematic Review Source Type: research